Fragment-Based Discovery of Novel MUS81 Inhibitors.


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
11 Jul 2024
Historique:
received: 13 10 2023
revised: 12 05 2024
accepted: 16 05 2024
medline: 17 7 2024
pubmed: 17 7 2024
entrez: 17 7 2024
Statut: epublish

Résumé

MUS81 is a structure-selective endonuclease that cleaves various branched DNA structures arising from natural physiological processes such as homologous recombination and mitosis. Due to this, MUS81 is able to relieve replication stress, and its function has been reported to be critical to the survival of many cancers, particularly those with dysfunctional DNA-repair machinery. There is therefore interest in MUS81 as a cancer drug target, yet there are currently few small molecule inhibitors of this enzyme reported, and no liganded crystal structures are available to guide hit optimization. Here we report the fragment-based discovery of novel small molecule MUS81 inhibitors with sub-μM biochemical activity. These inhibitors were used to develop a novel crystal system, providing the first structural insight into the inhibition of MUS81 with small molecules.

Identifiants

pubmed: 39015284
doi: 10.1021/acsmedchemlett.3c00453
pmc: PMC11247637
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1151-1158

Informations de copyright

© 2024 The Authors. Published by American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Auteurs

Gavin W Collie (GW)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Ulf Börjesson (U)

R&D, AstraZeneca, Gothenburg 431 83, Sweden.

Yunhua Chen (Y)

Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China.

Zhiqiang Dong (Z)

Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China.

Paolo Di Fruscia (P)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Andrea Gohlke (A)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Anna Hoyle (A)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Thomas A Hunt (TA)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Mehul H Jesani (MH)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Haiou Luo (H)

Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China.

Jakub Luptak (J)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Alexander G Milbradt (AG)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Priyanka Narasimhan (P)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Martin Packer (M)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Saleha Patel (S)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Jingchuan Qiao (J)

Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China.

R Ian Storer (RI)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Christopher J Stubbs (CJ)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Jonathan Tart (J)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Caroline Truman (C)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Anderson T Wang (AT)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Matthew G Wheeler (MG)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Jon Winter-Holt (J)

R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Classifications MeSH